title: What can we learn from phase II adjuvant trials in melanoma?
authors.forename: U
authors.initials: U
authors.lastname: Keilholz
authors.forename: S
authors.initials: S
authors.lastname: Suciu
authors.forename: A M
authors.initials: AM
authors.lastname: Eggermont
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002330:Carmustine / Q000008:administration & dosage; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D017322:Clinical Trials, Phase II as Topic; D003131:Combined Modality Therapy; D018849:Controlled Clinical Trials as Topic; D003606:Dacarbazine / Q000008:administration & dosage / Q000627:therapeutic use; D004357:Drug Synergism; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D007372:Interferons / Q000627:therapeutic use; D007376:Interleukin-2 / Q000627:therapeutic use; D008545:Melanoma / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D009362:Neoplasm Metastasis; D016032:Randomized Controlled Trials as Topic; D012107:Research Design; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D013629:Tamoxifen / Q000008:administration & dosage; D016896:Treatment Outcome; D014747:Vinblastine / Q000008:administration & dosage
chemical_list: D018906:Antineoplastic Agents, Alkylating; D007155:Immunologic Factors; D007376:Interleukin-2; D013629:Tamoxifen; D014747:Vinblastine; D003606:Dacarbazine; D007372:Interferons; D002945:Cisplatin; D002330:Carmustine